CD274 and neoplasm: The high proportion of PD-L1-expressing tumour cells in PSC suggests a promising therapeutic approach for the application of ICIs in patients with advanced tumour stages and possibly also for adjuvant or neoadjuvant therapy of sarcomatoid lung carcinomas in the early tumour stages.